February 11, 2019 11:36am

Q4/18 financial results is a scorecard of  (AKA) earnings of 45 covered  companies

3 out of 45 ...

The current LPS (loss per share) or net income, cash positions i.e. "runways" and correlation of "street" expectations - it's a reflection of this universe's investing "status"

Investors can gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.

 


COMPANY SYMBOL NET INCOME Q3/18 LOSS Q3/18 LPS Q3/18 CASH  RUNWAY
Aduro Biotech, Inc. ADRO          
Alnylam Pharmaceuticals ALNY  

-$211.4 M

FY -$761.5 M

-$2.09

-$7.57

$1.13 B Q4/21
Applied Genetic Technologies AGTC   -$4.2 M -$0.23 $96.1 M Q2-3/21
Asterias Biotherapeutics AST          
Athersys, Inc. ATHX          
Adverum Biotechnologies, Inc. ADVM          
Audentes Therapeutics BOLD          
AxoGen, Inc. AXGN          
Bellicum Pharmaceuticals, Inc. BLCM          
BioLife Solutions, Inc. BLFS          
BioMarin Pharmaceuticals BMRN          
Biostage, Inc. BSTG          
BioTime, Inc. BTX          
bluebird bio BLUE          
Brainstorm Cell Therapeutics Inc. BCLI          
Caladrius Biosciences. CLBS          
Cellectis SA CLLS          
Cesca Therapeutics, Inc KOOL          
CRISPR Therapeutics CRSP          
Editas Medicine EDIT          
Fate Therapeutics, Inc. FATE          
Global Blood Therapeutics GBT          
Histogenics Corporation HSGX          
Homology Medicine FIXX          
Intellia Therapeutics NTLA          
Intrexon Corporation XON          
Ionis Pharmaceuticals IONS          
Mesoblast Limited MESO          
MiMedx Group, Inc MDXG          
Neuralstem, Inc.  CUR          
Organovo Holdings, Inc. ONVO   -$6.5 M -$0.06 $35.2 M Q4/20
Osiris Therapeutics, Inc. OSIR          
Pluristem Therapeutics, Inc. PSTI          
ReNeuron Group PLC RENE.L          
Regenxbio RGNX          
Sage Therapeutics SAGE          
Sangamo Biosciences, Inc. SGMO          
Solid Biosciences SLDB          
Spark Therapeutics, Inc. ONCE          
Stemline Therapeutics, Inc. STML          
Ultragenyx RARE          
uniQure N.V. QURE          
Verastem, Inc. VSTM          
Vericel Corporation VCEL          
Voyager Therapeutics VYGR